Chemotherapy of increasing intensity in the treatment of chronic myelomonocytic leukemia (CMML).

被引：0
|
作者：
Beran, M [1 ]
Onida, F [1 ]
Cortes, JE [1 ]
O'Brien, S [1 ]
Giles, FJ [1 ]
Estey, E [1 ]
Keating, MJ [1 ]
Koller, CA [1 ]
Kantarjian, HM [1 ]
机构：
[1] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
BLOOD | 2001年 / 98卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2614
引用
收藏
页码：624A / 624A
页数：1
相关论文
共 50 条
  • [1] Chronic myelomonocytic leukemia (CMML)
    Geissler, Klaus
    WIENER MEDIZINISCHE WOCHENSCHRIFT, 2023, 173 (1-2) : 1 - 2
  • [2] Chronic myelomonocytic leukemia (CMML)
    Klaus Geissler
    Wiener Medizinische Wochenschrift, 2023, 173 : 1 - 2
  • [3] Efficacy of decitabine in the treatment of patients with chronic myelomonocytic leukemia (CMML).
    Wijermans, P. W.
    Luebbert, Michael
    Baer, Maria R.
    Slack, James L.
    BLOOD, 2006, 108 (11) : 756A - 757A
  • [4] Efficacy of decitabine in the treatment of patients with chronic myelomonocytic leukemia (CMML)
    Wijermans, P. W.
    Rueter, B.
    Baer, M. R.
    Slack, J. L.
    Saba, H. I.
    Luebbert, M.
    LEUKEMIA RESEARCH, 2008, 32 (04) : 587 - 591
  • [5] PREDICTIVE FACTORS FOR EVOLUTION FROM OLIGOMONOCYTIC CHRONIC MYELOMONOCYTIC LEUKEMIA (OM-CMML) TO CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML)
    Bravo David, Roman
    Rocha Leonor, Arenillas
    Maria Teresa, Asensi
    Nieves, Garcia-Gisbert
    Juan Jose, Rodriguez Sevilla
    Ruiz Brayan, Merchan
    Avila Sara, Garcia
    Paricio Beatriz, Bellosillo
    Maria Concepcion, Fernandez-Rodriguez
    Brichs Lourdes, Florensa
    del Alamo Ana, Ferrer
    Gonzalez Xavier, Calvo
    HAEMATOLOGICA, 2021, 106 (10) : 252 - 252
  • [6] PREDICTIVE FACTORS OF OLIGOMONOCYTIC CHRONIC MYELOMONOCYTIC LEUKEMIA (OM-CMML) EVOLUTION TO OVERT CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML)
    Roman, D.
    Arenillas, L.
    Asensi, M. T.
    Garcia-Gisbert, N.
    Rodriguez, J. J.
    Merchan, B.
    Garcia, S.
    Bellosillo, B.
    Fernandez, M. C.
    Florensa, L.
    Ferrer, A.
    Calvo, X.
    LEUKEMIA RESEARCH, 2021, 108 : S14 - S14
  • [7] Risk assessment in chronic myelomonocytic leukemia (CMML)
    Germing, U
    Kündgen, A
    Gattermann, N
    LEUKEMIA & LYMPHOMA, 2004, 45 (07) : 1311 - 1318
  • [8] CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML) PATIENTS WITH LYSOZYME NEPHROPATHY AND CMML RENAL
    Lafargue, Marie-Camille
    Van Huyen, Jean-Paul Duong
    Isnard, Pierre
    Rennke, Helmut
    Essig, Marie
    Carre, Martin
    Mercadal, Lucile
    Farhi, Jonathan
    Bobot, Mickael
    Sakhi, Hamza
    Comont, Thibault
    Golbin, Leonard
    Chemouny, Jonathan
    Cambier, Nathalie
    Laribi, Kamel
    Selamet, Umut
    Riella, Leonardo
    Fain, Olivier
    Ades, Lionel
    Fenaux, Pierre
    Cohen, Camille
    Mekinian, Arsene
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2023, 38 : I380 - I381
  • [9] Clinical Outcomes of Oligomonocytic Chronic Myelomonocytic Leukemia (OM-CMML) and Predictive Factors of Evolution of OM-CMML into Overt Chronic Myelomonocytic Leukemia (CMML)
    Roman-Bravo, David
    Arenillas, Leonor
    Asensi, Maria Teresa
    Garcia-Gisbert, Nieves
    Rodriguez-Sevilla, Juan Jose
    Merchan, Brayan
    Avila, Sara Garcia
    Bellosillo, Beatriz
    Fernandez-Rodriguez, Concepcion
    Florensa, Lourdes
    Ferrer, Ana
    Calvo, Xavier
    BLOOD, 2021, 138
  • [10] PROGNOSTIC FACTORS IN ADULT CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML)
    FENAUX, P
    BEUSCART, R
    JOUET, JP
    BAUTERS, F
    BLUT, 1988, 56 (06): : C12 - C12
12345